Ian G. Mills
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ian G. Mills has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- David Edgar Neal
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
3 shared publications A. Ramos-Montoya
1 shared publication- Abhi Veerakumarasivam
Medical Genetics Laboratory, Genetics and Regenerative Medicine Research Centre, Faculty of Medicine and Health Sciences, University Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia
1 shared publication - Anne Y. Warren
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
1 shared publication C.E. Massie
1 shared publication- Charles E. Massie
Cancer Research UK Cambridge Institute, University of Cambridge, CB2 0RE Cambridge, UK
1 shared publication
Latest Publications
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e942-e942a
942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man
- 29 February 2012
- Published by Elsevier in European Urology Supplements
- Vol. 11 (1) , e942-e942a
942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man
- 16 October 2006
- Published by Wiley in The Prostate
- Vol. 67 (2) , 190-202
A role for neurotensin in bicalutamide resistant prostate cancer cells
BACKGROUND Anti-androgens are administered as a principal treatment for prostate cancer. Aggressive hormone refractory disease is characterized in some cases by the development of a neuroendocrine phenotype. However little attention has been paid to resistance pathways selected for by long-term treatment with non-steroidal anti-androgens. METHODS Using a resistant sub-line, LNCaP-Bic, we performed a comparative gene expression profiling using cDNA microarrays and target validation by qRT-PCR. Targets were then explored using cell proliferation, cell cycle analysis and in vitro invasion assays using siRNA technology. RESULTS Neurotensin/Neuromedin N (NTS) was upregulated in the LNCaP-Bic line at both the transcript and protein level. The resistant line was found to have an increased proliferation rate, more rapid cell cycle progression and increased invasiveness through Matrigel. Each phenotypic difference could be reduced using siRNA knockdown of NT. CONCLUSION Increased expression of NT in bicalutamide resistant prostate cancer cells induces cell proliferation and invasion suggesting that this peptide may contribute to the development of bicalutamide resistant prostate cancer. Prostate
- 16 October 2006
- Published by Wiley in The Prostate
- Vol. 67 (2) , 190-202
A role for neurotensin in bicalutamide resistant prostate cancer cells
BACKGROUND Anti-androgens are administered as a principal treatment for prostate cancer. Aggressive hormone refractory disease is characterized in some cases by the development of a neuroendocrine phenotype. However little attention has been paid to resistance pathways selected for by long-term treatment with non-steroidal anti-androgens. METHODS Using a resistant sub-line, LNCaP-Bic, we performed a comparative gene expression profiling using cDNA microarrays and target validation by qRT-PCR. Targets were then explored using cell proliferation, cell cycle analysis and in vitro invasion assays using siRNA technology. RESULTS Neurotensin/Neuromedin N (NTS) was upregulated in the LNCaP-Bic line at both the transcript and protein level. The resistant line was found to have an increased proliferation rate, more rapid cell cycle progression and increased invasiveness through Matrigel. Each phenotypic difference could be reduced using siRNA knockdown of NT. CONCLUSION Increased expression of NT in bicalutamide resistant prostate cancer cells induces cell proliferation and invasion suggesting that this peptide may contribute to the development of bicalutamide resistant prostate cancer. Prostate
- 13 April 2006
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (5) , 403-409
The developing role of receptors and adaptors
Recent data indicate that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might change our understanding of their role in cancer, and do these findings have implications for drug resistance? The response of a cell to the myriad of signals that it receives is varied, and it is dependent on many different factors. The most-studied responses involve growth-factor signalling and these signalling cascades have become key targets for cancer therapy. Recent reports have indicated that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might affect our understanding of their role in cancer and have implications for drug resistance?
- 13 April 2006
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 6 (5) , 403-409
The developing role of receptors and adaptors
Recent data indicate that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might change our understanding of their role in cancer, and do these findings have implications for drug resistance? The response of a cell to the myriad of signals that it receives is varied, and it is dependent on many different factors. The most-studied responses involve growth-factor signalling and these signalling cascades have become key targets for cancer therapy. Recent reports have indicated that growth-factor receptors and associated adaptors can accumulate in the nucleus. Are there novel functions for these proteins that might affect our understanding of their role in cancer and have implications for drug resistance?
- Open Access
- 18 July 2005
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 170 (2) , 191-200
Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors
Internalization of activated receptors regulates signaling, and endocytic adaptor proteins are well-characterized in clathrin-mediated uptake. One of these adaptor proteins, huntingtin interacting protein 1 (HIP1), induces cellular transformation and is overexpressed in some prostate cancers. We have discovered that HIP1 associates with the androgen receptor through a central coiled coil domain and is recruited to DNA response elements upon androgen stimulation. HIP1 is a novel androgen receptor regulator, significantly repressing transcription when knocked down using a silencing RNA approach and activating transcription when overexpressed. We have also identified a functional nuclear localization signal at the COOH terminus of HIP1, which contributes to the nuclear translocation of the protein. In conclusion, we have discovered that HIP1 is a nucleocytoplasmic protein capable of associating with membranes and DNA response elements and regulating transcription.
- 18 July 2005
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 170 (2) , 191-200
Open AccessHuntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors
Internalization of activated receptors regulates signaling, and endocytic adaptor proteins are well-characterized in clathrin-mediated uptake. One of these adaptor proteins, huntingtin interacting protein 1 (HIP1), induces cellular transformation and is overexpressed in some prostate cancers. We have discovered that HIP1 associates with the androgen receptor through a central coiled coil domain and is recruited to DNA response elements upon androgen stimulation. HIP1 is a novel androgen receptor regulator, significantly repressing transcription when knocked down using a silencing RNA approach and activating transcription when overexpressed. We have also identified a functional nuclear localization signal at the COOH terminus of HIP1, which contributes to the nuclear translocation of the protein. In conclusion, we have discovered that HIP1 is a nucleocytoplasmic protein capable of associating with membranes and DNA response elements and regulating transcription.